Heghine Khachatryan: Addressing Critical Gaps in Cancer-Associated VTE
Heghine Khachatryan, Editor-in-Chief of Hemostasis Today, Head of Hemophilia and Thrombosis Center at Yeolyan Hematology and Oncology Center, reposted from RPTH Journal on LinkedIn, adding:
”Cancer-associated VTE: an old problem, still unresolved
Despite decades of research, cancer-associated venous thromboembolism (VTE) remains a major cause of morbidity and mortality.
This timely editorial in Research and Practice in Thrombosis and Haemostasis highlights critical gaps—from real-time epidemiologic data to optimal thromboprophylaxis and bleeding risk stratification—and points toward future, cancer-specific solutions.
A strong reminder that prevention, individualized risk assessment, and innovation in anticoagulation must remain a global priority in oncology and hematology.
Editorial by Alok Khorana
Research and Practice in Thrombosis and Haemostasis”
Quoting RPTH Journal‘s post:
”Cancer-associated VTE: an old problem, still unresolved
RPTH Journal Editorial by Alok Khorana
As highlighted by Maiocco et al. in RPTH Journal, it remains puzzling that VTE, a complication of cancer known since the 19th century, continues to heavily burden modern oncology care.
- Cancer patients face a 9- to 20-fold higher risk of VTE, even with contemporary therapies
- In a nationwide US inpatient analysis, 8.1% of cancer-related hospitalizations were complicated by VTE
- VTE remains strongly associated with higher mortality, longer hospital stays, and higher costs
- Despite decades of awareness, robust evidence for inpatient thromboprophylaxis in cancer patients is still lacking
Read the editorial here
Read the study by Giuseppe Maiocco et al here”
Title: The public health impact of cancer-associated venous thromboembolism: looking to the future
Authors: Alok Khorana
Read the Full Editorial on RPTH Journal

Stay updated on all scientific advances with Hemostasis Today.
-
Oct 5, 2026, 15:31Irma Bagdoniene: Multidisciplinary Management of High-Risk Familial Hypercholesterolaemia and CAD
-
Oct 5, 2026, 15:00Serena Williams and Pulmonary Embolism: From Personal Crisis to Lessons in Venous Thromboembolism
-
Oct 5, 2026, 14:55Marco Moscarelli: 3D Reconstruction Enhances Volumetric Assessment of Post-TAVI Thrombosis
-
Oct 5, 2026, 13:24Abdul Muqtadir Abbasi: Diagnostic Pearls for Evaluating Isolated Thrombocytopenia in Residents
-
Oct 5, 2026, 13:16Katerina Pavenski: Rethinking What ‘Normal’ Means for Iron Deficiency
-
Oct 5, 2026, 13:09Rick Matthews: Balancing Established VTE Partnerships with Innovative Interventional Technologies
-
Oct 5, 2026, 13:01Nawsherwan Mohammad: Recognizing TTP Before the ADAMTS13 Result Arrives
-
Oct 5, 2026, 12:51Bruno Pougault: The Hidden Challenges Behind Anti Xa Testing
-
Oct 5, 2026, 12:41Syed Huzaifa Khan: Rethinking CTRP12 as a Biomarker for In Stent Restenosis